126
|
Inamo Y, Ryou N, Abe O, Fuchigami S, Hashimoto K, Fuchigami T, Hayashi K. A case report: a pediatric patient with acute lupus hemophagocytic syndrome; differences from reactive hemophagocytosis caused by hypercytokinemia. Mod Rheumatol 2014; 12:72-5. [DOI: 10.3109/s101650200012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
127
|
Ohuchi M, Hashimoto K, Ushiba A, Kishimoto T, Yamane T, Hamamoto T, Tabata T, Tsujita Y, Matsushiga M, Takahashi K, Matsumura K, Fujino K, Eguchi Y. Plasma platelet-derived microparticles to platelet count ratio as a marker of mortality in critically ill patients. Crit Care 2014. [PMCID: PMC4068881 DOI: 10.1186/cc13400] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
128
|
Cha I, Yagi Y, Kawahara T, Hashimoto K, Fujiki K, Tamesue S, Yamauchi T, Tsubokawa N. Grafting of polymers onto graphene oxide by trapping of polymer radicals and ligand-exchange reaction of polymers bearing ferrocene moieties. Colloids Surf A Physicochem Eng Asp 2014. [DOI: 10.1016/j.colsurfa.2013.10.002] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
129
|
Hashimoto K, Roxanis I, Generali D, Andreis D, Strina C, Cappelletti M, Macaulay V, Kong A. Abstract P6-05-08: Nuclear HER3 localisation plays a role in trastuzumab resistance in HER2-positive breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p6-05-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: HER3 is known to locate in the nucleus. Unlike HER4, nuclear HER3 translocation has not been reported to be due to a proteolytic cleavage process by ADAM17 and gamma-secretase. The mechanisms of nuclear HER3 induction and its role in relation to trastuzumab treatment and resistance for HER2-positive breast cancer is unclear.
Methods: Using nuclear fractionation and confocal microscopy, nuclear HER3 localisation was investigated in response to trastuzumab with or without ADAM17 inhibitor and gamma-secretase inhibitor in a panel of HER2 expressing cell lines. We also correlated nuclear HER3 expression by immunohistochemistry with treatment response in patients who underwent window trastuzumab study as well as the survival outcome in a cohort of HER2-positive breast cancer patients using Kaplan–Meier survival curves with Log-rank test.
Results: HER3 ligand heregulin and trastuzumab was found to induce nuclear HER3 translocation in HER2-positive breast cancer cell lines, including SKBR3. Nuclear HER3 was also enriched in acquired trastuzumab resistant SKBR3 cells (SKBr3-TR). Trastuzumab treatment induced several HER3 fragments and HER3100kD was found to be responsible for nuclear HER3 enrichment by fractionation. This fragment was confirmed to be a specific band of HER3 as shown by HER3 knockdown. Nuclear HER3 was reduced by inhibiting either gamma-secretase or ADAM17 inhibitor. Gamma-secretase or ADAM17 inhibitor reduced HER3100kD in both SKBr3 and SKBr3-TR cells.
In HER2-positive breast cancer patients who underwent window trastuzumab study, baseline nuclear HER3 status was not a predictor of response for trastuzumab monotherapy at day 21. However, nuclear HER3 was enriched after trastuzumab treatment in a poor-responder patient. Total HER3 expression level in cytoplasm positively was correlated with poor response to trastuzumab monotherapy in HER2-positive patients (r = 0.67, p = 0.05). There was no statistically significant difference in disease-free survival between positive and negative nuclear HER3 expression but the number of patients was small (n = 87). Further validation to assess nuclear HER3 expression as a prognostic and predictive biomarker in HER2-positive breast cancer patients undergoing trastuzumab treatment will be assessed in randomized tumour samples from FinHER study.
Conclusion: Heregulin and trastuzumab treatment seems to induce nuclear HER3 translocation in some of the HER2 positive breast cancer cells. This may be due to proteolytic cleavage of HER3 as it is reduced by ADAM17 or gamma-secretase inhibitor. Enriched nuclear localisation of HER3 seems to be one possible mechanism of acquired resistance to trastuzumab in HER2-positive breast cancer.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P6-05-08.
Collapse
|
130
|
Yamauchi H, Hashimoto K, Iwata T, Hiramatsu R, Fukuda T, Hosaka T. Abstract P3-08-03: Establishing Japanese model “working ring” - Informational, emotional and problem-solving group intervention for working breast cancer survivors. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p3-08-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Due to advancement of cancer treatment, the number of cancer survivors is increasing and our society also needs to consider cancer survivorship. Especially the prevalence of breast cancer by age is much younger in Japan than in western countries. About half of them were diagnosed in 30-50’s, and they are considered strong working force in society.
Cancer and its treatment largely affect their working status, therefore support system for workers with cancer is urgently required.
Methods: We established support systems by 3 phases. We assessed the effect of breast cancer and informational needs in Japanese young breast cancer survivors for working with cancer (Phase 1). We also estimated economic impact due to such work force loss from cancer (Phase 2). Furthermore, we designed intervention model “Working Ring” by health care providers for cancer survivors to facilitate returning to work or keeping their job, and evaluated its effect (Phase3).
Results: Among 42 young (less than 35 years old) breast cancer survivors who worked at the time of diagnosis, 33% of them had to changed their role at work after diagnosis of breast cancer. Focused interview revealed they needed informational and emotional support system. According to the Japanese Health Ministry of Health, Labor and Welfare database, we estimated total economic loss due to cancer treatment, $1569 million for women and $2959 million for men. Breast cancer is estimated as a number one cause of economic loss among cancer survivors in Japan. Finally, we introduced group intervention for working survivors provided by health care professionals (psycho-oncologist, nurse, and medical social worker) and labor and social security attorney. In this “Working Ring”, patients were given information about working status, practical issues provided by their companies and our society in order to maintain their work. We enrolled total 22 working breast cancer survivors divided in 3 groups; each group was given by 3 sessions of one-hour group intervention. All attendees of the group intervention showed increase in knowledge and problem solving technique concerning working, and QOL improvement by using POMS.
Discussion: We noted that there are many unmet needs for working breast cancer survivors and loss of their job causes enormous impact for social economy. Surprisingly, breast cancer is estimated number one cause of economic loss from cancer diagnosis in Japan. It is urgently required to establish support systems for working cancer survivors. Our group interventional model “Working Ring” was very successful to improve their anxiety and informational needs. We are currently extending this model through entire Japan.
Conclusions: Most of cancer survivors are considered to be potential working force. To establish a support system for them to maintain working ability and environment is necessary for societal reintegration.
(This work is supported by a Grant-in-Aid for Cancer research from the Japanese Health Ministry of Health, Labor and Welfare, H24-Ganrinsho-ippan-011).
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-08-03.
Collapse
|
131
|
Waghray A, Nassar A, Hashimoto K, Eghtesad B, Aucejo F, Krishnamurthi V, Uso TD, Srinivas T, Steiger E, Abu-Elmagd K, Quintini C. Combined intestine and kidney transplantation in a patient with encapsulating peritoneal sclerosis: case report. Am J Transplant 2013; 13:3274-7. [PMID: 24266976 DOI: 10.1111/ajt.12505] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2013] [Revised: 09/05/2013] [Accepted: 09/06/2013] [Indexed: 01/25/2023]
Abstract
Encapsulating peritoneal sclerosis (EPS) is a rare but devastating complication of peritoneal dialysis characterized by fibrosis and calcification of the intestine that, in severe cases, can progress to intestinal failure and total parenteral nutrition dependency. Medical and surgical interventions carry a poor prognosis in these patients. We describe a case of a 36-year-old female with end-stage kidney disease and severe EPS not amenable to surgical intervention who underwent a combined intestinal and kidney transplantation. At 3 years posttransplantation, the patient has normal intestinal and kidney function. This represents, to our knowledge, the first report of severe EPS and end-stage kidney disease treated with a combined transplant.
Collapse
|
132
|
Hasumi Y, Numata A, Kubota K, Tsukazaki T, Hashimoto K, Horie K, Yokota H. End of Life Care at a Gynecologic Oncology Unit. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt460.90] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
133
|
Osawa K, Miyoshi T, Koyama Y, Hashimoto K, Nagase S, Nakamura K, Kohno K, Morita H, Kusano K, Ito H. Usefulness of first-pass myocardial perfusion imaging at rest in combination with 64-row detector computed tomography angiography for assessing coronary artery disease. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht308.896] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
134
|
Motoki K, Miyoshi T, Oe H, Hashimoto K, Nagase S, Nakamura K, Kohno K, Morita H, Kusano K, Ito H. Impaired endothelial function in the brachial artery predicts clinical poor outcome in patients with stable angina pectoris undergoing successful coronary revascularization. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht308.p2488] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
135
|
Adare A, Afanasiev S, Aidala C, Ajitanand NN, Akiba Y, Akimoto R, Al-Bataineh H, Al-Ta'ani H, Alexander J, Angerami A, Aoki K, Apadula N, Aphecetche L, Aramaki Y, Armendariz R, Aronson SH, Asai J, Asano H, Aschenauer EC, Atomssa ET, Averbeck R, Awes TC, Azmoun B, Babintsev V, Bai M, Baksay G, Baksay L, Baldisseri A, Bannier B, Barish KN, Barnes PD, Bassalleck B, Basye AT, Bathe S, Batsouli S, Baublis V, Baumann C, Baumgart S, Bazilevsky A, Belikov S, Belmont R, Bennett R, Berdnikov A, Berdnikov Y, Bickley AA, Bing X, Blau DS, Boissevain JG, Bok JS, Borel H, Boyle K, Brooks ML, Buesching H, Bumazhnov V, Bunce G, Butsyk S, Camacho CM, Campbell S, Castera P, Chang BS, Chang WC, Charvet JL, Chen CH, Chernichenko S, Chi CY, Chiba J, Chiu M, Choi IJ, Choi JB, Choi S, Choudhury RK, Christiansen P, Chujo T, Chung P, Churyn A, Chvala O, Cianciolo V, Citron Z, Cleven CR, Cole BA, Comets MP, Connors M, Constantin P, Csanád M, Csörgő T, Dahms T, Dairaku S, Danchev I, Das K, Datta A, Daugherity MS, David G, Deaton MB, Dehmelt K, Delagrange H, Denisov A, d'Enterria D, Deshpande A, Desmond EJ, Dharmawardane KV, Dietzsch O, Ding L, Dion A, Donadelli M, Drapier O, Drees A, Drees KA, Dubey AK, Durham JM, Durum A, Dutta D, Dzhordzhadze V, D'Orazio L, Edwards S, Efremenko YV, Egdemir J, Ellinghaus F, Emam WS, Engelmore T, Enokizono A, En'yo H, Esumi S, Eyser KO, Fadem B, Fields DE, Finger M, Finger M, Fleuret F, Fokin SL, Fraenkel Z, Frantz JE, Franz A, Frawley AD, Fujiwara K, Fukao Y, Fusayasu T, Gadrat S, Gainey K, Gal C, Garishvili A, Garishvili I, Glenn A, Gong H, Gong X, Gonin M, Gosset J, Goto Y, Granier de Cassagnac R, Grau N, Greene SV, Grosse Perdekamp M, Gunji T, Guo L, Gustafsson HÅ, Hachiya T, Hadj Henni A, Haegemann C, Haggerty JS, Hahn KI, Hamagaki H, Hamblen J, Han R, Hanks J, Harada H, Hartouni EP, Haruna K, Hashimoto K, Haslum E, Hayano R, He X, Heffner M, Hemmick TK, Hester T, Hiejima H, Hill JC, Hobbs R, Hohlmann M, Hollis RS, Holzmann W, Homma K, Hong B, Horaguchi T, Hori Y, Hornback D, Huang S, Ichihara T, Ichimiya R, Ide J, Iinuma H, Ikeda Y, Imai K, Imrek J, Inaba M, Inoue Y, Iordanova A, Isenhower D, Isenhower L, Ishihara M, Isobe T, Issah M, Isupov A, Ivanischev D, Jacak BV, Javani M, Jia J, Jiang X, Jin J, Jinnouchi O, Johnson BM, Joo KS, Jouan D, Jumper DS, Kajihara F, Kametani S, Kamihara N, Kamin J, Kaneta M, Kaneti S, Kang BH, Kang JH, Kang JS, Kanou H, Kapustinsky J, Karatsu K, Kasai M, Kawall D, Kawashima M, Kazantsev AV, Kempel T, Khanzadeev A, Kijima KM, Kikuchi J, Kim BI, Kim C, Kim DH, Kim DJ, Kim E, Kim EJ, Kim HJ, Kim KB, Kim SH, Kim YJ, Kim YK, Kinney E, Kiriluk K, Kiss Á, Kistenev E, Kiyomichi A, Klatsky J, Klay J, Klein-Boesing C, Kleinjan D, Kline P, Kochenda L, Kochetkov V, Komatsu Y, Komkov B, Konno M, Koster J, Kotchetkov D, Kotov D, Kozlov A, Král A, Kravitz A, Krizek F, Kubart J, Kunde GJ, Kurihara N, Kurita K, Kurosawa M, Kweon MJ, Kwon Y, Kyle GS, Lacey R, Lai YS, Lajoie JG, Layton D, Lebedev A, Lee B, Lee DM, Lee J, Lee K, Lee KB, Lee KS, Lee MK, Lee SH, Lee SR, Lee T, Leitch MJ, Leite MAL, Leitgab M, Leitner E, Lenzi B, Lewis B, Li X, Liebing P, Lim SH, Linden Levy LA, Liška T, Litvinenko A, Liu H, Liu MX, Love B, Luechtenborg R, Lynch D, Maguire CF, Makdisi YI, Makek M, Malakhov A, Malik MD, Manion A, Manko VI, Mannel E, Mao Y, Mašek L, Masui H, Masumoto S, Matathias F, McCumber M, McGaughey PL, McGlinchey D, McKinney C, Means N, Mendoza M, Meredith B, Miake Y, Mibe T, Mignerey AC, Mikeš P, Miki K, Miller TE, Milov A, Mioduszewski S, Mishra DK, Mishra M, Mitchell JT, Mitrovski M, Miyachi Y, Miyasaka S, Mohanty AK, Moon HJ, Morino Y, Morreale A, Morrison DP, Motschwiller S, Moukhanova TV, Mukhopadhyay D, Murakami T, Murata J, Nagae T, Nagamiya S, Nagata Y, Nagle JL, Naglis M, Nagy MI, Nakagawa I, Nakamiya Y, Nakamura KR, Nakamura T, Nakano K, Nattrass C, Nederlof A, Newby J, Nguyen M, Nihashi M, Niida T, Norman BE, Nouicer R, Novitzky N, Nyanin AS, O'Brien E, Oda SX, Ogilvie CA, Ohnishi H, Oka M, Okada K, Omiwade OO, Onuki Y, Oskarsson A, Ouchida M, Ozawa K, Pak R, Pal D, Palounek APT, Pantuev V, Papavassiliou V, Park BH, Park IH, Park J, Park SK, Park WJ, Pate SF, Patel L, Pei H, Peng JC, Pereira H, Peresedov V, Peressounko DY, Petti R, Pinkenburg C, Pisani RP, Proissl M, Purschke ML, Purwar AK, Qu H, Rak J, Rakotozafindrabe A, Ravinovich I, Read KF, Rembeczki S, Reuter M, Reygers K, Reynolds R, Riabov V, Riabov Y, Richardson E, Roach D, Roche G, Rolnick SD, Romana A, Rosati M, Rosen CA, Rosendahl SSE, Rosnet P, Rukoyatkin P, Ružička P, Rykov VL, Sahlmueller B, Saito N, Sakaguchi T, Sakai S, Sakashita K, Sakata H, Samsonov V, Sano M, Sano S, Sarsour M, Sato S, Sato T, Sawada S, Sedgwick K, Seele J, Seidl R, Semenov AY, Semenov V, Sen A, Seto R, Sharma D, Shein I, Shevel A, Shibata TA, Shigaki K, Shimomura M, Shoji K, Shukla P, Sickles A, Silva CL, Silvermyr D, Silvestre C, Sim KS, Singh BK, Singh CP, Singh V, Skutnik S, Slunečka M, Soldatov A, Soltz RA, Sondheim WE, Sorensen SP, Soumya M, Sourikova IV, Sparks NA, Staley F, Stankus PW, Stenlund E, Stepanov M, Ster A, Stoll SP, Sugitate T, Suire C, Sukhanov A, Sun J, Sziklai J, Tabaru T, Takagi S, Takagui EM, Takahara A, Taketani A, Tanabe R, Tanaka Y, Taneja S, Tanida K, Tannenbaum MJ, Tarafdar S, Taranenko A, Tarján P, Tennant E, Themann H, Thomas TL, Todoroki T, Togawa M, Toia A, Tojo J, Tomášek L, Tomášek M, Tomita Y, Torii H, Towell RS, Tram VN, Tserruya I, Tsuchimoto Y, Tsuji T, Vale C, Valle H, van Hecke HW, Vargyas M, Vazquez-Zambrano E, Veicht A, Velkovska J, Vértesi R, Vinogradov AA, Virius M, Vossen A, Vrba V, Vznuzdaev E, Wagner M, Walker D, Wang XR, Watanabe D, Watanabe K, Watanabe Y, Watanabe YS, Wei F, Wei R, Wessels J, White SN, Winter D, Wolin S, Wood JP, Woody CL, Wright RM, Wysocki M, Xie W, Yamaguchi YL, Yamaura K, Yang R, Yanovich A, Yasin Z, Ying J, Yokkaichi S, You Z, Young GR, Younus I, Yushmanov IE, Zajc WA, Zaudtke O, Zelenski A, Zhang C, Zhou S, Zimányi J, Zolin L. Medium modification of jet fragmentation in Au+Au collisions at √[s(NN)]=200 GeV measured in direct photon-hadron correlations. PHYSICAL REVIEW LETTERS 2013; 111:032301. [PMID: 23909311 DOI: 10.1103/physrevlett.111.032301] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/17/2012] [Indexed: 06/02/2023]
Abstract
The jet fragmentation function is measured with direct photon-hadron correlations in p+p and Au+Au collisions at √[s(NN)]=200 GeV. The p(T) of the photon is an excellent approximation to the initial p(T) of the jet and the ratio z(T)=p(T)(h)/p(T)(γ) is used as a proxy for the jet fragmentation function. A statistical subtraction is used to extract the direct photon-hadron yields in Au+Au collisions while a photon isolation cut is applied in p+p. I(AA), the ratio of hadron yield opposite the photon in Au+Au to that in p+p, indicates modification of the jet fragmentation function. Suppression, most likely due to energy loss in the medium, is seen at high z(T). The associated hadron yield at low z(T) is enhanced at large angles. Such a trend is expected from redistribution of the lost energy into increased production of low-momentum particles.
Collapse
|
136
|
Inamo Y, Hayashi R, Saito K, Hasegawa M, Nakamura A, Hashimoto K, Fuchigami T, Nishikomori R. A Japanese pediatric patient with coexisting systemic lupus erythematosus and familial Mediterranean fever. Lupus 2013; 22:1056-9. [PMID: 23861027 DOI: 10.1177/0961203313497117] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
This case report describes a Japanese girl with systemic lupus erythematosus who had recurrent fevers and erythema nodosum. She was later found to carry the complex allele E148Q/R202Q/P369S/R408Q of MEFV, the gene responsible for familial Mediterranean fever.
Collapse
|
137
|
Hashimoto K, Kasamaki Y, Okumura Y, Nakai T, Kunimoto S, Hiro T, Wtanabe I, Nagashima M, Nakayama T, Hirayama A, Soma M. Reference intervals of late potentials and association with the autonomic nervous system in healthy subjects using Holter ambulatory electrocardiogram. J Electrocardiol 2013. [DOI: 10.1016/j.jelectrocard.2013.05.083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
138
|
Saito S, Lin YC, Murayama Y, Hashimoto K, Yokoyama KK. Human amnion-derived cells as a reliable source of stem cells. Curr Mol Med 2013; 12:1340-9. [PMID: 23016591 DOI: 10.2174/156652412803833625] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2012] [Revised: 09/13/2012] [Accepted: 09/19/2012] [Indexed: 11/22/2022]
Abstract
Human amnion-derived cells possess great potential for the repair of human neural disorders, and recent studies have broadened the spectrum for applications because they exhibit the characteristics of multipotent stem cells. These cells express embryonic stem cell markers such as Oct4, Nanog, Sox2, SSEA-3, SSEA-4 and Rex1, and can differentiate into multiple primary germ layers both in vitro and in vivo. Moreover, induced pluripotent stem cells have been generated from amnion-derived cells by virus-mediated delivery of three or four pluripotency-relating transcription factors or by the introduction of only one transcription factor with electroporation. Because human amnion-derived cells are readily available, less likely to contain genetic aberrations and can be reprogrammed earlier and more efficiently than differentiated cells, they can be ideal resources as the donor pluripotent stem cells for therapeutic purposes. We discuss here the highlights of recent studies and potential applications of human amnion-derived multipotent stem cells to stem cell biology as well as to regenerative medicine in the field of aging, heart disease, diabetes and neural disorders.
Collapse
|
139
|
Kabuki S, Sonoda S, Hatsukawa Y, Kimura H, Asai M, Hashimoto K, Komura S, Kubo H, Matsuoka Y, Mizumoto T, Nagai Y, Nakamura S, Sato T, Sawano T, Takada A, Toyoshima A, Tsukada K, Kunieda E, Tanimori T. SU-C-144-01: Imaging Study of An Electron-Tracking Compton Camera for Nuclear Medicine. Med Phys 2013. [DOI: 10.1118/1.4813990] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
140
|
Hashimoto K, Todo T. Mitotic slippage underlies the relationship between p53 dysfunction and the induction of large micronuclei by colcemid. Mutagenesis 2013; 28:457-64. [DOI: 10.1093/mutage/get021] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
|
141
|
Hashimoto K, Saito T, Machuca T, Linacre V, Nakajima D, Azad S, Waddell T, Liu M, Cypel M, Keshavjee S. Apoptosis, Not Necrosis, during Ex-Vivo Lung Perfusion Is Correlated with Severe PGD. J Heart Lung Transplant 2013. [DOI: 10.1016/j.healun.2013.01.907] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
142
|
Noguchi T, Makino S, Shinahara M, Nishiyama M, Hashimoto K, Terada Y. Effects of gold thioglucose treatment on central corticotrophin-releasing hormone systems in mice. J Neuroendocrinol 2013; 25:340-9. [PMID: 23253150 DOI: 10.1111/jne.12011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/04/2012] [Revised: 12/01/2012] [Accepted: 12/08/2012] [Indexed: 11/27/2022]
Abstract
Systemic administration of gold thioglucose (GTG) causes a hypothalamic lesion that extends from the ventral part of the ventromedial hypothalamus (VMH) to the dorsal part of the arcuate nucleus (ARC), resulting in hyperphagia and obesity in mice. In the present study, we used in situ hybridisation histochemistry to explore the effects of GTG on the central corticotrophin-releasing hormone (CRH) system, which regulates feeding and energy homeostasis. Type 2 CRH receptor (CRHR-2) mRNA expression decreased by 40% at 8 weeks in the VMH and by 40-60% at 2 and 8 weeks in the ARC after GTG injection. By contrast, CRHR-2 mRNA expression in the hypothalamic paraventricular nucleus (PVN) and lateral septum was unchanged. Urocortin (Ucn) 3 mRNA expression in the perifornical area and medial amygdala decreased, whereas CRH mRNA expression in the PVN increased at 2 and 8 weeks after GTG injection. Ucn 1 mRNA expression in the Edingher-Westphal nucleus and Ucn 2 mRNA expression in the PVN were unchanged. Because Ucn 3 is an anorexigenic and a possible endogenous ligand for VMH CRHR-2, our results suggest that decreased Ucn 3 expression and decreased VMH CRHR-2 expression contribute, in part, to GTG-induced hyperphagia and obesity. To determine whether VMH CRHR-2 mediates the anorexigenic effects of Ucn 3, Ucn 3 was administered i.c.v. and food intake was measured 8 weeks after GTG treatment. Ucn 3 decreased cumulative food intake on days 4-7 after surgery compared to i.c.v. administration of vehicle in control mice. By contrast, the anorexigenic effects of i.c.v. Ucn 3 were abolished in GTG-treated mice. Taken together, our results indicate that the Ucn 3 pathway, which innervates the VMH, is involved in appetite regulation via CRHR-2. It remains to be determined whether CRHR-2 in the ARC has additional roles in appetite regulation by Ucn 3.
Collapse
|
143
|
Ochiai A, Harada K, Hashimoto K, Shibata K, Ishiyama Y, Mitsui T, Tanaka T, Taniguchi M. α-Amylase is a potential growth inhibitor of Porphyromonas gingivalis
, a periodontal pathogenic bacterium. J Periodontal Res 2013; 49:62-8. [DOI: 10.1111/jre.12079] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/13/2013] [Indexed: 12/19/2022]
|
144
|
Hirata A, Tachikawa Y, Hashimoto K, Sakai H, Kaneko A, Suzuki J, Eguchi K, Shigematsu K, Nikami H, Yanai T. Spontaneous T/NK-cell Lymphoma associated with Simian Lymphocryptovirus in a Japanese Macaque (Macaca fuscata). J Comp Pathol 2013; 148:43-6. [DOI: 10.1016/j.jcpa.2012.05.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2011] [Revised: 04/04/2012] [Accepted: 05/02/2012] [Indexed: 02/04/2023]
|
145
|
Niijima K, Muranaka Y, Ando T, Okada S, Niijima Y, Hashimoto K, Yamada M, Ohshima K, Mori M, Ono K. Elevated 1-h plasma glucose following 75-g oral glucose load is a predictor of arterial stiffness in subjects with normal glucose tolerance. Diabet Med 2012; 29:e457-60. [PMID: 23002926 DOI: 10.1111/dme.12026] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
AIMS The study aimed to investigate arterial stiffness in subjects with normal glucose tolerance. METHODS BMI, systolic blood pressure, fasting plasma glucose, lipid variables, ankle-brachial pressure index and brachial-ankle pulse wave velocity were measured in 2059 subjects from Takasaki city, located approximately 100 km north of Tokyo in Japan. Following a 75-g oral glucose tolerance test, only subjects with normal glucose tolerance were selected. RESULTS One-hour post-challenge plasma glucose levels were correlated with brachial-ankle pulse wave velocity values (r = 0.340, P < 0.0001). When subjects with normal glucose tolerance were divided into three groups-group 1 (1-h plasma glucose < 8.56 mmol/l, n = 1595), group 2 (1-h plasma glucose ≥ 8.56 and < 10.17 mmol/l, n = 334) and group 3 (1-h plasma glucose ≥ 10.17 mmol/l, n = 130)-the brachial-ankle pulse wave velocity of group 3 (1473 ± 322 cm/s) was significantly higher than that of group 2 (1355 ± 252 cm/s) and brachial-ankle pulse wave velocity of group 2 was also significantly higher than that of group 1 (1275 ± 212 cm/s). CONCLUSIONS We have identified that, in normal glucose tolerance, arterial stiffness is advanced in subjects with higher 1-h post-challenge plasma glucose in spite of the normal range for BMI, systolic blood pressure, fasting plasma glucose and lipid variables. Higher 1-h plasma glucose level is a risk factor for arterial stiffness in normal glucose tolerance.
Collapse
|
146
|
Sumi H, Yabuki M, Iwai K, Hashimoto K, Kosugi Y, Yoshimatsu M, Ishikawa T, Yoshida S. 73 Antitumor Activities and Pharmacodynamic Biomarkers of a Novel and Orally Available Small Molecule IAP Antagonist. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71871-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
147
|
Arai S, Shibata Y, Nakamura Y, Kashiwagi B, Uei T, Tomaru Y, Miyashiro Y, Honma S, Hashimoto K, Sekine Y, Ito K, Sasano H, Suzuki K. Development of prostate cancer in a patient with primary hypogonadism: intratumoural steroidogenesis in prostate cancer tissues. Andrology 2012; 1:169-74. [PMID: 23258647 DOI: 10.1111/j.2047-2927.2012.00026.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2012] [Revised: 09/10/2012] [Accepted: 09/10/2012] [Indexed: 11/29/2022]
Abstract
Intratumoural steroidogenesis may play a significant role in the progression of prostate cancer (PC) in the context of long-term ablation of circulating testosterone (T). To clarify the mechanism accounting for the progression of PC in a 74-year-old man who had undergone bilateral orchiectomy when he was 5 years old, we performed immunohistochemical studies of androgen receptor (AR) and steroidogenic enzymes in the prostate. We also measured steroid hormone levels in the serum and prostate, as well as mRNA levels of genes mediating androgen metabolism in the prostate. Positive nuclear staining of AR was detected in malignant epithelial cells. The levels of androstenedione (Adione), T, and 5-alpha dihydrotestosterone (DHT) in the serum of the patient were similar to those in PC patients receiving neoadjuvant androgen deprivation therapy (ADT), but were higher in the patient's prostate than in PC patients not receiving ADT. The gene expression of CYP17A1 and HSD3B1 was not detected, whereas that of STS, HSD3B2, AKR1C3, SRD5A1, and SRD5A2 was detected. Moreover, cytoplasmic staining of HSD3B2, AKR1C3, SRD5A1, and SRD5A2 was detected in malignant epithelial cells. Hence, in the present case (a man with primary hypogonadism), steroidogenesis in PC tissues from adrenal androgens, especially dehydroepiandrosterone sulphate, was the mechanism accounting for progression of PC. This mechanism might help elucidate the development of castration-resistant PC.
Collapse
|
148
|
Adare A, Afanasiev S, Aidala C, Ajitanand NN, Akiba Y, Akimoto R, Al-Ta'ani H, Alexander J, Angerami A, Aoki K, Apadula N, Aramaki Y, Asano H, Aschenauer EC, Atomssa ET, Awes TC, Azmoun B, Babintsev V, Bai M, Bannier B, Barish KN, Bassalleck B, Bathe S, Baublis V, Baumgart S, Bazilevsky A, Belmont R, Berdnikov A, Berdnikov Y, Bing X, Blau DS, Boyle K, Brooks ML, Buesching H, Bumazhnov V, Butsyk S, Campbell S, Castera P, Chen CH, Chi CY, Chiu M, Choi IJ, Choi JB, Choi S, Choudhury RK, Christiansen P, Chujo T, Chvala O, Cianciolo V, Citron Z, Cole BA, Connors M, Csanád M, Csörgő T, Dairaku S, Datta A, Daugherity MS, David G, Denisov A, Deshpande A, Desmond EJ, Dharmawardane KV, Dietzsch O, Ding L, Dion A, Donadelli M, Drapier O, Drees A, Drees KA, Durham JM, Durum A, D'Orazio L, Edwards S, Efremenko YV, Engelmore T, Enokizono A, Esumi S, Eyser KO, Fadem B, Fields DE, Finger M, Finger M, Fleuret F, Fokin SL, Frantz JE, Franz A, Frawley AD, Fukao Y, Fusayasu T, Gainey K, Gal C, Garishvili A, Garishvili I, Glenn A, Gong X, Gonin M, Goto Y, Granier de Cassagnac R, Grau N, Greene SV, Grosse Perdekamp M, Gunji T, Guo L, Gustafsson HÅ, Hachiya T, Haggerty JS, Hahn KI, Hamagaki H, Hanks J, Hashimoto K, Haslum E, Hayano R, He X, Hemmick TK, Hester T, Hill JC, Hollis RS, Homma K, Hong B, Horaguchi T, Hori Y, Huang S, Ichihara T, Iinuma H, Ikeda Y, Imrek J, Inaba M, Iordanova A, Isenhower D, Issah M, Isupov A, Ivanischev D, Jacak BV, Javani M, Jia J, Jiang X, Johnson BM, Joo KS, Jouan D, Kamin J, Kaneti S, Kang BH, Kang JH, Kang JS, Kapustinsky J, Karatsu K, Kasai M, Kawall D, Kazantsev AV, Kempel T, Khanzadeev A, Kijima KM, Kim BI, Kim C, Kim DJ, Kim EJ, Kim HJ, Kim KB, Kim YJ, Kim YK, Kinney E, Kiss A, Kistenev E, Klatsky J, Kleinjan D, Kline P, Komatsu Y, Komkov B, Koster J, Kotchetkov D, Kotov D, Král A, Krizek F, Kunde GJ, Kurita K, Kurosawa M, Kwon Y, Kyle GS, Lacey R, Lai YS, Lajoie JG, Lebedev A, Lee B, Lee DM, Lee J, Lee KB, Lee KS, Lee SH, Lee SR, Leitch MJ, Leite MAL, Leitgab M, Lewis B, Lim SH, Linden Levy LA, Litvinenko A, Liu MX, Love B, Maguire CF, Makdisi YI, Makek M, Malakhov A, Manion A, Manko VI, Mannel E, Masumoto S, McCumber M, McGaughey PL, McGlinchey D, McKinney C, Mendoza M, Meredith B, Miake Y, Mibe T, Mignerey AC, Milov A, Mishra DK, Mitchell JT, Miyachi Y, Miyasaka S, Mohanty AK, Moon HJ, Morrison DP, Motschwiller S, Moukhanova TV, Murakami T, Murata J, Nagae T, Nagamiya S, Nagle JL, Nagy MI, Nakagawa I, Nakamiya Y, Nakamura KR, Nakamura T, Nakano K, Nattrass C, Nederlof A, Nihashi M, Nouicer R, Novitzky N, Nyanin AS, O'Brien E, Ogilvie CA, Okada K, Oskarsson A, Ouchida M, Ozawa K, Pak R, Pantuev V, Papavassiliou V, Park BH, Park IH, Park SK, Pate SF, Patel L, Pei H, Peng JC, Pereira H, Peresedov V, Peressounko DY, Petti R, Pinkenburg C, Pisani RP, Proissl M, Purschke ML, Qu H, Rak J, Ravinovich I, Read KF, Reynolds R, Riabov V, Riabov Y, Richardson E, Roach D, Roche G, Rolnick SD, Rosati M, Rukoyatkin P, Sahlmueller B, Saito N, Sakaguchi T, Samsonov V, Sano M, Sarsour M, Sawada S, Sedgwick K, Seidl R, Sen A, Seto R, Sharma D, Shein I, Shibata TA, Shigaki K, Shimomura M, Shoji K, Shukla P, Sickles A, Silva CL, Silvermyr D, Sim KS, Singh BK, Singh CP, Singh V, Slunečka M, Soltz RA, Sondheim WE, Sorensen SP, Soumya M, Sourikova IV, Stankus PW, Stenlund E, Stepanov M, Ster A, Stoll SP, Sugitate T, Sukhanov A, Sun J, Sziklai J, Takagui EM, Takahara A, Taketani A, Tanaka Y, Taneja S, Tanida K, Tannenbaum MJ, Tarafdar S, Taranenko A, Tennant E, Themann H, Todoroki T, Tomášek L, Tomášek M, Torii H, Towell RS, Tserruya I, Tsuchimoto Y, Tsuji T, Vale C, van Hecke HW, Vargyas M, Vazquez-Zambrano E, Veicht A, Velkovska J, Vértesi R, Virius M, Vossen A, Vrba V, Vznuzdaev E, Wang XR, Watanabe D, Watanabe K, Watanabe Y, Watanabe YS, Wei F, Wei R, White SN, Winter D, Wolin S, Woody CL, Wysocki M, Yamaguchi YL, Yang R, Yanovich A, Ying J, Yokkaichi S, You Z, Younus I, Yushmanov IE, Zajc WA, Zelenski A, Zolin L. Evolution of π(0) suppression in Au+Au collisions from √(s(NN))=39 to 200 GeV. PHYSICAL REVIEW LETTERS 2012; 109:152301. [PMID: 23102299 DOI: 10.1103/physrevlett.109.152301] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/08/2012] [Indexed: 06/01/2023]
Abstract
Neutral-pion π(0) spectra were measured at midrapidity (|y|<0.35) in Au+Au collisions at √(s(NN))=39 and 62.4 GeV and compared with earlier measurements at 200 GeV in a transverse-momentum range of 1<p(T)<10 GeV/c. The high-p(T) tail is well described by a power law in all cases, and the powers decrease significantly with decreasing center-of-mass energy. The change of powers is very similar to that observed in the corresponding spectra for p+p collisions. The nuclear modification factors (R(AA)) show significant suppression, with a distinct energy, centrality, and p(T) dependence. Above p(T)=7 GeV/c, R(AA) is similar for √(s(NN))=62.4 and 200 GeV at all centralities. Perturbative-quantum-chromodynamics calculations that describe R(AA) well at 200 GeV fail to describe the 39 GeV data, raising the possibility that, for the same p(T) region, the relative importance of initial-state effects and soft processes increases at lower energies. The p(T) range where π(0) spectra in central Au+Au collisions have the same power as in p+p collisions is ≈5 and 7 GeV/c for √(s(NN))=200 and 62.4 GeV, respectively. For the √(s(NN))=39 GeV data, it is not clear whether such a region is reached, and the x(T) dependence of the x(T)-scaling power-law exponent is very different from that observed in the √(s(NN))=62 and 200 GeV data, providing further evidence that initial-state effects and soft processes mask the in-medium suppression of hard-scattered partons to higher p(T) as the collision energy decreases.
Collapse
|
149
|
Taniyama T, Hashimoto K, Hirakawa A, Katsumata N, Kodaira M, Yonemori K, Yunokawa M, Shimizu C, Tamura K, Ando M, Fujiwara Y. The Estimation of Life-Time for the Patients who Acquired Resistance to Standard Chemotherapies. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32433-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
150
|
Hasumi Y, Kubota K, Numata A, Tsukazaki T, Hashimoto K, Horie K, Yokota H. Treatment Patterns and Prognosis of Figo Stage IVB Cervical Cancer. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32473-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|